NCT06121349Completed
WOE of Anti-CD20 Therapies
The Wearing-off Effect of Anti-CD20 Therapies in Patients With Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 11 Jul 2025
Brief summary (registry, in English)
The nature, intensity, and prevalence of this wearing-off effect remain poorly understood. To our knowledge, there is no consensus in the literature on what symptoms constitute a wearing-off effect, nor is there a single validated scale that measures wearing-off effect. The current study will explore the wearing-off effect associated with OCR and OMB, using a variety of validated scales assessing MS symptoms (i.e., fatigue, mobility, pain, depression, cognition), as well as some global questions on wearing-off. In addition, impact of worsening of MS symptoms on patients' health-related quality of life (HRQoL) and their work productivity will be assessed using relevant MS-specific validated scales
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 157 (actual)
- First submitted
- 31 Oct 2023
- Start date
- 4 Dec 2023
- Primary completion date
- 13 Jun 2025
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Multiple sclerosis
- NCT number
- NCT06121349
What you commit to
- Study type: Observational
- Participants enrolled: 157
- From 4 Dec 2023 to the primary completion date, 13 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently participating in a clinical trial involving MS drugs
- Last Ocrevus infusion was less than 3 months back
- OMB sample:
- Currently participating in a clinical trial involving MS drugs
Other
- OCR sample:
Who the study is looking for
- OCR sample:
- Self-reported diagnosis of RMS, SPMS or CIS
- ≥21 years old at the time of initial contact
- Under treatment with OCR at the time of initial contact
- Have been on OCR for ≥ 1 year at the time of initial contact (i.e., prevalent users)
- Able to answer the questionnaires in English
- OMB sample
- Self-reported diagnosis of RMS, SPMS or CIS
- ≥21 years old at the time of initial contact
- Under treatment with OMB at the time of initial contact
- Have been on OMB for ≥6 months at the time of initial contact (i.e., prevalent users)
- Able to answer the questionnaires in English
Age in the registry: 21 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | East Hanover | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.